Pfizer

    PFIZER
    Pharma
    ₹3,841.80
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹17,575 Cr

    P/E
    23.08
    Day range
    ₹3,791.00 – ₹3,858.40
    52-week range
    ₹3,589.00 – ₹5,257.00
    Volume
    13,177
    Open
    ₹3,813.90
    Prev close
    ₹3,814.00

    Latest results · Q2 FY27(standalone)Revenue ₹727 Cr-41.6%Profit ₹313 Cr-17.7%Margin 43.1%YoY vs the same quarter last year

    No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.

    Research profile

    Composite 58 / 100

    Factor percentiles

    Value68
    Quality76
    Momentum15
    Low volatility75

    Derived metrics

    Earn. yield
    4.3%
    Graham no.
    ₹1,941.14
    vs Graham
    -49.5%
    ROE ÷ P/B
    4.3%
    12-1 mom.
    -25.8%
    Return / vol
    -1.05
    Magic Formula
    #99
    Piotroski
    3/5
    FCF yield
    5.4%
    PEG
    0.35

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    PfizerPFIZER₹17,575 Cr23.083.9817.1%24.0%36.0%0.04+13.2%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 2d ago

    Headlines about Pfizer from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    22.0
    Price / Book
    4.01
    ROE (FY26)
    17.1%
    ROCE (latest year)
    24%
    Dividend yield
    1.96%

    Moving averages (NSE)

    20-day
    ₹3,782
    Price above
    50-day
    ₹3,912.62
    Price below
    200-day
    ₹4,533.42
    Price below

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +1.3%
    Profit 3Y CAGR
    +5.0%
    Revenue YoY (Sep 2026)
    +13.2%
    Profit YoY (Sep 2026)
    +65.6%
    Operating margin
    36.0%
    Net margin
    43.1%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr200 Cr400 Cr600 Cr800 Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%20%40%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • DII
    • Public
    • FII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-2K Cr-1K Cr0 Cr1K Cr2K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%10%20%30%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr2K Cr4K Cr6K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date.

    FY18FY19FY20FY21FY22FY23FY24FY25FY26FY27₹0₹100₹200₹300₹400

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales540547563589538592603642645629653727
    YoY Sales growth-13-5——0———————
    Expenses387357385399392364393412417393406466
    Operating Profit153189177189146228210230228236248261
    OPM %28%35%32%32%27%38%35%36%35%38%38%36%
    Other Income44754243432176742-205045179
    Interest372223322213
    Depreciation181415151516141414151414
    Profit before tax176244203215172426260255192269277423
    Tax %26%27%26%26%26%22%26%26%26%26%26%26%
    Net Profit130179151158128331192189142200204313
    EPS in Rs₹28.41₹39.10₹32.94₹34.61₹27.89₹72.34₹41.91₹41.32₹31.00₹43.68₹44.70₹68.47

    From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days26

    +8 days since Mar 2021

    Inventory Days195

    -4 days since Mar 2021

    Days Payable89

    -41 days since Mar 2021

    Cash Conversion Cycle132

    +45 days since Mar 2021

    Working Capital Days9

    +6 days since Mar 2021

    Strengths, risks & growth

    Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors primarily in India. [1] It is the 3rd largest multinational pharmaceutical company in India. [2]

    Strengths

    • Company is almost debt free.
    • Company has been maintaining a healthy dividend payout of 58.3%

    Risks

    • The company has delivered a poor sales growth of 2.39% over past five years.

    Compounded Sales Growth

    10 Years
    +2%
    5 Years
    +2%
    3 Years
    +1%
    TTM
    +12%

    Compounded Profit Growth

    10 Years
    +10%
    5 Years
    +9%
    3 Years
    +8%
    TTM
    +13%

    Stock Price CAGR

    10 Years
    +8%
    5 Years
    -6%
    3 Years
    -1%
    1 Year
    -25%

    Return on Equity

    10 Years
    +17%
    5 Years
    +18%
    3 Years
    +17%
    Last Year
    +18%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter63.92%63.92%63.92%63.92%0.00 pp
    FII2.71%2.81%1.65%1.63%-0.02 pp
    DII17.05%16.89%17.80%17.52%-0.28 pp
    Public16.32%16.36%16.62%16.93%+0.31 pp

    Filed with NSE for Sept 2026: promoters 63.92%, public 36.08%

    Analysts & fund holdings

    80%
    80% recommend buy
    5 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E23.1 vs 45.1
    Sector P/B6.03
    Beta0.81

    Who holds the shares, quarter by quarter

    Mutual funds 12.83% (+0.15 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters63.9%
    • Foreign institutions1.6%
    • Mutual funds12.8%
    • Insurance4.7%
    • Other domestic institutions0.0%
    • Retail11.7%
    • Others5.2%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Quant Small Cap Fund3.44%1.77%+0.48 pp
    Nippon India Small Cap Fund2.55%0.58%-0.16 pp
    ICICI Pru Healthcare Fund0.95%2.33%+0.36 pp
    Nippon India Multi Cap Fund0.77%0.25%-0.06 pp
    ICICI Pru Small Cap Fund0.75%1.44%-0.36 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    24.0%
    Downside volatility
    22.6%
    Worst 5% of days
    2.5%
    Average of that tail
    3.3%
    Max drawdown (1Y)
    34.7%
    Below its peak
    30.5%

    Against the market

    Beta vs Nifty 50
    0.62
    Correlation
    0.35
    Relative strength (3M)
    -24.3%
    ATR (14)
    2.5%

    Return

    Return 1M
    +0.7%
    Return 3M
    -20.4%
    Return 6M
    -20.9%
    Return 1Y
    -25.3%
    vs 200-day average
    -15.3%

    Momentum

    RSI (14)
    49.0
    MACD histogram
    19.76
    Stochastic %K
    65.2
    ADX (14)
    19.2
    +DI / −DI
    19.6 / 21.6
    Money flow index
    70.4

    Participation

    Delivery (20d avg)
    50.7%
    vs its 60-day baseline
    -2.6 pts
    Volume vs 20-day
    -0.4σ
    Close vs day's VWAP
    +0.3%
    52-week position
    12 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    3 of 5 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — passed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — failed
    • Current ratio improving — passed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — not testableneeds total income and expenses a year apart
    • Asset turnover improving — failed
    Free cash flow
    ₹942 Cr
    FCF yield
    5.4%
    Net debt
    ₹104 Cr
    Net debt / equity
    0.02
    PEG
    0.35
    Revenue CAGR
    13.2%
    Profit CAGR
    65.7%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    • dividend
      ₹75.00

      Dividend - Rs 75 Per Share

      17 Jul 2026
      ex-date
    • dividend
      ₹35.00

      Dividend - Rs 35 Per Share & Special Dividend Of Rs 100 Per Share/ Special Dividend Of Rs 30

      9 Jul 2025
      ex-date
    • dividend
      ₹35.00

      Dividend - Rs 35 Per Share

      21 Aug 2024
      ex-date
    • dividend
      ₹35.00

      Dividend - Rs 35 Per Share/ Special Dividend - Rs 5 Per Share

      11 Aug 2023
      ex-date
    • dividend
      ₹30.00

      Special Dividend - Rs 30 Per Share

      19 Sept 2022
      ex-date
    • dividend
      ₹35.00

      Dividend - Rs 35 Per Share

      18 Aug 2022
      ex-date
    • dividend
      ₹30.00

      Annual General Meeting/Dividend - Rs 30 Per Share/Special Dividend - Rs 5 Per Share

      11 Aug 2021
      ex-date
    • dividend
      ₹10.00

      Annual General Meeting/Dividend - Rs 10 Per Share

      27 Aug 2020
      ex-date
    • dividend
      ₹320.00

      Special Dividend - Rs 320 Per Share

      6 May 2020
      ex-date
    • dividend
      ₹22.50

      Dividend - Rs 22.50 Per Share

      1 Aug 2019
      ex-date
    • dividend
      ₹20.00

      Annual General Meeting/Dividend- Rs 20 Per Share

      29 Aug 2018
      ex-date
    • dividend
      ₹15.00

      Dividend Rs 15/- Per Share + Special Dividend Rs 5/- Per Share

      22 Aug 2017
      ex-date
    • dividend
      ₹15.00

      Dividend - Rs.15/- Per Share

      27 Jun 2016
      ex-date
    • dividend
      ₹12.50

      Annual General Meeting And Dividend Rs.12.50 Per Share

      3 Jul 2015
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      29 Oct 2014
      ex-date
    • dividend
      ₹360.00

      Interim Dividend - Rs 360/- Per Share

      5 Dec 2013
      ex-date
    • dividend
      ₹12.50

      Annual General Meeting / Dividend - Rs 12.50/- Per Share + Special Dividend - Rs 20/- Per Share

      28 Aug 2013
      ex-date
    • dividend
      ₹12.50

      Annual General Meeting/ Dividend Rs 12.50 Per Share

      24 Jul 2012
      ex-date
    • dividend
      ₹4.00

      Dividend-Rs.4/- Per Share

      8 Jul 2011
      ex-date
    • dividend
      ₹12.50

      Interim Dividend-Rs.12.50 Per Share

      20 Jan 2011
      ex-date

    Company announcements

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Please find attached Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Please find enclosed copy of newspaper advertisements for Transfer and Dematerialisation of Physical Securities.

    Insider Trading / SAST
    Closure of Trading Window

    Intimation for Closure of Trading Window.

    Company Update
    Intimation Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

    Intimation for order issued by the Deputy/Additional Commissioner of Income Tax Transfer Pricing.

    Company Update
    Announcement under Regulation 30 (LODR)-Change in Management

    Intimation regarding change in Senior Management Personnel of the Company.

    Others
    Board Meeting Outcome for Discontinuation Of Minipress XL.

    Please find enclosed outcome of the Board Meeting held today i.e., September 7, 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Advertisement - Special Window for Re- lodgement of Transfer and Dematerialisation of Physical Securities.

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Pursuant to Regulation 44 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015, we submit herewith the consolidated Scrutinizer's Report of the votes cast through ....

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Pursuant to Regulation 30 of SEBI LODR Regulations, 2015, please find enclosed proceedings of the 75th Annual General Meeting of the Company held on July 28, 2026.

    Board Meeting
    Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results For The Quarter Ended June 30, 2026.

    Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Unaudited Financial Results of the Company for ....

    Company Update
    Announcement under Regulation 30 (LODR)-Change in Directorate

    Intimation of Resignation of Mr. Amit Agarwal, Executive Director -Finance & Chief Financial Officer

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Board Meeting To Consider And Approve The Unaudited Financial Results For The Quarter Ended June 30, 2026.

    Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2026 ,inter alia, to consider and approve This is to inform that a meeting of ....

    Company Update
    Response To Clarification Sought By BSE Limited.

    Response to clarification sought with reference to news item appearing in 'The Hindu BusinessLine'

    Company UpdatePrice-sensitive
    Clarification sought from Pfizer Ltd

    The Exchange has sought clarification from Pfizer Ltd on July 17, 2026, with reference to news appeared in https://www.thehindubusinessline.com/ dated July 17, 2026 quoting "Pfizer suspends ....

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026

    Filed with BSE (scrip 500680); the last 45 days. Documents open at bseindia.com.

    SEBI filings & orders

    From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.

    Buybacks, open offers & rights issues

    Regulatory orders

    • Order

      Consent Order in the matter of Pfizer Limited

      22 Feb 2010
      Read on SEBI

    Documents

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 4 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Pfizer: common questions

    Answered from the figures on this page.

    Pfizer last traded at ₹3,841.80 (NSE, as of 18 Nov 2026). The last session moved it up 0.73%.

    Pfizer is valued at about ₹17,575 crore (NSE, as of 18 Nov 2026).

    Pfizer trades at a price-to-earnings ratio of 23.08 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Pfizer has traded between ₹3,589.00 and ₹5,257.00 over the past 52 weeks, to 18 Nov 2026. It is currently 15% of the way up that range.

    Pfizer (PFIZER) is classified under Pharma on this site's screener.